Covid-19
RCT | Another study shows Ivermectin does not benefit patients with Covid-19
22 Feb, 2023 | 12:45h | UTCSummary: The study aimed to evaluate whether Ivermectin, at a maximum dose of 600 μg/kg daily for 6 days, shortened symptom duration or prevented hospitalization among outpatients with mild to moderate COVID-19. A total of 1206 US adults were enrolled in the double-blind, randomized, placebo-controlled platform trial, with follow-up data through November 10, 2022. The study found that the median time to sustained recovery was 11 days in both the ivermectin and placebo groups. Among those receiving Ivermectin, 5.7% were hospitalized, died, or had urgent or emergency care visits compared with 6.0% receiving placebo. These findings, along with all the previous studies to date, do not support using Ivermectin in patients with mild to moderate COVID-19.
Editorials:
At a Higher Dose and Longer Duration, Ivermectin Still Not Effective Against COVID-19 – JAMA
The Ethics of Clinical Research: Managing Persistent Uncertainty – JAMA
Related:
RCT | Ivermectin does not improve time to recovery in outpatients with mild to moderate COVID-19.
RCT | Metformin, Ivermectin, and Fluvoxamine are not beneficial for obese outpatients with Covid-19.
Ivermectin for COVID-19 Cochrane review update: 11 trials and no evidence of benefit shown.
RCT: Early treatment with ivermectin does not improve outcomes in patients with Covid-19.
Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.
Long-term consequences of the misuse of ivermectin data.
Ivermectin: How false science created a Covid ‘miracle’ drug.
Fraudulent ivermectin studies open up new battleground between science and misinformation.
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Ivermectin: Cochrane’s most talked about review so far, ever. Why?
Flawed ivermectin preprint highlights challenges of COVID drug studies.
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
Why was a major study on ivermectin for covid-19 just retracted?
RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.
RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
Review | Comorbidities, multimorbidity and COVID-19
22 Feb, 2023 | 12:39h | UTCComorbidities, multimorbidity and COVID-19 – Nature Medicine
Cohort Study | One third of patients hospitalized with Covid-19 persist with lung abnormalities after 2 years
21 Feb, 2023 | 11:47h | UTCSummary: The study aimed to assess changes in chest CT abnormalities and pulmonary function in patients two years after recovery from SARS-CoV-2 infection. The prospective study followed 144 participants discharged from the hospital after SARS-CoV-2 infection between January 15 and March 10, 2020. The participants underwent serial chest CT scans and pulmonary function tests at 6 months, 12 months, and 2 years after symptom onset. The study found that 39% of participants had persistent interstitial lung abnormalities at 2 years, and this was associated with respiratory symptoms and decreased diffusion pulmonary function.
Editorial: Radiologic Findings after COVID-19 and the Correlation with Lung Function – Radiology
Commentaries:
Post-COVID-19 CT scans show lung abnormalities persist two years later – News Medical
COVID’s aftermath: Persistent organ damage at 1 year, lung abnormalities at 2 – CIDRAP
RCT | Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age
17 Feb, 2023 | 13:27h | UTCSummary: The study was a combined phase 2-3 clinical trial that aimed to determine whether the BNT162b2 vaccine was safe, could elicit an immune response and was effective in preventing COVID-19 in healthy children. The trial was conducted on children aged 6 months to 11 years, with the findings presented for the 6 months to 4 years age group. The results indicated that the vaccine was safe, immunogenic, and effective in reducing the risk of symptomatic COVID-19 by 73.2% in children aged 6 months to 4 years. The vaccine was well-tolerated, and the side effects were mainly mild to moderate. The incidence of fever was similar among those who received the vaccine or a placebo.*
Article: Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age – New England Journal of Medicine (link to abstract – $ for full-text)
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Excess mortality among US physicians during the COVID-19 pandemic
16 Feb, 2023 | 15:14h | UTCExcess Mortality Among US Physicians During the COVID-19 Pandemic – JAMA Internal Medicine
Commentaries:
More than 600 US doctors died than expected early in COVID pandemic – CIDRAP
Hundreds of U.S. Doctors Lost Their Lives During Pandemic – HealthDay
Commentary on Twitter
From March 2020 to December 2021, US physicians experienced over 600 more deaths than expected, but substantially fewer than the US general population. Older physicians who provide direct patient care were at the highest risk. https://t.co/7Un0h7VC8X
— JAMA Internal Medicine (@JAMAInternalMed) February 8, 2023
Cohort Study | Incidence of acute cardiac events during COVID-19-associated hospitalizations
15 Feb, 2023 | 16:05h | UTC
RCT | Pegylated Interferon Lambda reduces hospitalizations in predominantly vaccinated outpatients with Covid-19
9 Feb, 2023 | 14:03h | UTCEarly Treatment with Pegylated Interferon Lambda for Covid-19 – New England Journal of Medicine
RCT | BCG vaccine not effective for preventing COVID-19 and other respiratory tract infections in older adults
9 Feb, 2023 | 13:53h | UTCNews Release: Tuberculosis vaccine does not protect elderly against COVID-19, finds large Dutch study – University Medical Center Utrecht
Commentary on Twitter
Bacillus Calmette-Guérin vaccine in ineffective in prevention of COVID-19 and other respiratory tract infections in older adults with comorbiditieshttps://t.co/dS4h1bq3Ns
— Clinical Microbiology and Infection (@CMIJournal) February 1, 2023
Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19
9 Feb, 2023 | 13:50h | UTC
Review | Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome
8 Feb, 2023 | 12:38h | UTC
Commentary on Twitter
In our latest Comment, Fedorowski & Sutton discuss the role of autonomic dysfunction and postural orthostatic tachycardia syndrome (POTS) in post-acute #COVID19 syndrome: https://t.co/gJ08XxnfQ6 pic.twitter.com/FmC9JwDs4C
— Nature Reviews Cardiology (@NatRevCardiol) February 2, 2023
Opinion | Let’s do the Cochrane review of physical measures to reduce the spread of viruses
7 Feb, 2023 | 14:11h | UTCOriginal Study: SR | Physical interventions to interrupt or reduce the spread of respiratory viruses
Related: Hospital masking should be optional – Sensible Medicine
RCT | Paxlovid did not improve outcomes in hospitalized patients with Covid-19
7 Feb, 2023 | 14:08h | UTC
M-A | Heparin full-dose anticoagulation is beneficial for non-critically ill COVID-19 patients
7 Feb, 2023 | 14:06h | UTCRelated:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Opinion | Hospital masking should be optional
6 Feb, 2023 | 13:37h | UTCHospital masking should be optional – Sensible Medicine
Related: SR | Physical interventions to interrupt or reduce the spread of respiratory viruses
Case-control study | Estimation of vaccine effectiveness of CoronaVac and BNT162b2 in patients with SARS-CoV-2 Omicron
6 Feb, 2023 | 13:32h | UTC
Commentary on Twitter
The CoronaVac and BNT162b2 (Pfizer) vaccines were effective against severe outcomes due to Omicron (74-77%), but protection among older individuals in Hong Kong was more likely to wane 6 months after the second dose; boosters can bring effectiveness >90%. https://t.co/kqgwryJ1kT
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
The next generation of coronavirus vaccines: a graphical guide
3 Feb, 2023 | 14:18h | UTCThe next generation of coronavirus vaccines: a graphical guide – Nature
Review | Current and emerging knowledge of diagnostic imaging in COVID-19
2 Feb, 2023 | 15:04h | UTCCurrent and Emerging Knowledge in COVID-19 – Radiology
See also:
Long-term Lung Abnormalities Associated with COVID-19 Pneumonia – Radiology
An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia – Radiology
The IDSA Guidelines on the diagnosis of COVID-19: antigen testing
1 Feb, 2023 | 13:37h | UTC
Assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US
1 Feb, 2023 | 13:36h | UTCNews Release: COVID-19 is a leading cause of death in children and young people in the US – University of Oxford
Related:
SR | Physical interventions to interrupt or reduce the spread of respiratory viruses
31 Jan, 2023 | 14:11h | UTCPhysical interventions to interrupt or reduce the spread of respiratory viruses – Cochrane Library
Commentary on Twitter (thread – click for more)
Just out Cochrane review on Physical interventions to interrupt or reduce the spread of respiratory viruses https://t.co/fI4Ac6VbAa
— Carl Heneghan (@carlheneghan) January 30, 2023
FDA panel eyes shift to annual COVID shots
30 Jan, 2023 | 01:03h | UTCFDA panel eyes shift to annual COVID shots – CIDRAP
See also:
FDA advisers recommend updating Covid vaccines – STAT
U.S. Proposes to Make COVID Shot Annual, Much Like Flu Shot – HealthDay
Case Series | Higher Troponin was associated with persistent cardiac MRI lesions in children with myocarditis after mRNA-based COVID-19 vaccination
30 Jan, 2023 | 01:01h | UTC
Perspective | Were bivalent boosters worth it? The biggest questions about the newest Covid-19 vaccines are still unanswered
27 Jan, 2023 | 12:19h | UTC
SR | Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease
26 Jan, 2023 | 12:47h | UTCNews Release: University of Calgary and WHO researchers find hybrid immunity is the best protection against COVID-19
Commentaries:
Review finds hybrid immunity provides best protection against Omicron – CIDRAP
Review | Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT)
26 Jan, 2023 | 12:46h | UTCSpotlight on vaccine-induced thrombosis and thrombocytopenia (VITT) – Blood